Featured

November 16, 2019

Carisma therapeutics announces investor conference participation

Carisma Therapeutics announced today that it will be participating in three upcoming investor conferences: Stifel 2019 Healthcare Conference, November 19-20, 2019 – Carisma’s management will deliver a presentation on Wednesday, November 20, at 4:45 pm EDT and host one-on-one meetings at the venue. The conference will be held at the Lotte New York Palace Hotel, New York, NY. Jefferies 2019 London […]

Read More

News

November 16, 2019

Carisma therapeutics announces investor conference participation

Carisma Therapeutics announced today that it will be participating in three upcoming investor conferences: Stifel 2019 Healthcare Conference, November 19-20, 2019 – Carisma’s management will deliver a presentation on Wednesday, November 20, at 4:45 pm EDT and host one-on-one meetings at the venue. The conference will be held at the Lotte New York Palace Hotel, New York, NY. Jefferies 2019 London […]

Read More
October 21, 2019

Carisma shares unique engineered macrophage cell therapy approach at the inaugural macrophage-directed therapies summit

Carisma’s VP of Business Development, Dora Mitchell, PhD and VP of Discovery Research, Michael Klichinsky, PharmD, PhD chaired and presented at the inaugural macrophage-directed therapies summit taking place October 22-24, 2019 in Boston, MA. The summit is the only platform dedicated to exploring the translation of macrophage therapies into the clinic. For full agenda and […]

Read More
September 9, 2019

Carisma Enters into a Research Collaboration with Phio Pharmaceuticals

“Metastatic solid tumors have been an intractable challenge for engineered cell therapies. Our platform technology, based on the genetically engineered macrophage, has a unique opportunity to provide benefit in this disease state,” said Dr. Michael Klichinsky, co-Founder and Vice President of Discovery at Carisma. “We are excited to work with Phio to evaluate sd-rxRNA mediated […]

Read More
June 3, 2019

Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer

Carisma Therapeutics is excited to welcome Robert Petit, PhD as its Chief Scientific Officer. Dr. Petit is an accomplished immuno-oncology scientist, innovator and drug developer, and a C-level executive with 25 years of experience in building and leading scientific, translational, and clinical development teams in public and private companies. View press release here.

Read More
May 9, 2019

Michael Klichinsky, VP of Discovery Research, Presents at the CAR-T and the Rise of Cellicon Valley Conference

Carisma’s Michael Klichinsky, VP of Discovery Research, joins leaders in cell therapy to present at the CAR-T and the Rise of Cellicon Valley conference to be held May 9-10, 2019 at the University of Pennsylvania (Penn). The forum is presented by Penn’s Abramson Cancer Center, the Children’s Hospital of Philadelphia and Penn’s Center for Cellular […]

Read More